B. Gulyas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
B. Gulyas has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
L. Farde
Department of Clinical Neuroscience, Karolinska Institutet, Center for Psychiatric Research, Stockholm, Sweden
13 shared publications- Christer Halldin
Department of Biophysics and Radiation Biology, HUN-REN TKI, Semmelweis University, 1094 Budapest, Hungary
11 shared publications C. Halldin
Karolinska Institutet, Department of Clinical Neuroscience, Psychiatry Section, Karolinska Hospital, Stockholm, Sweden
6 shared publicationsH.V. Wikström
Allbay AB; Hamburgsund; Sweden
6 shared publicationsB. Bang-Andersen
Lundbeck Research Denmark, H. Lundbeck A/S, Valby, Denmark
4 shared publications- Denis Guilloteau
UMR INSERM U930, Université François Rabelais de Tours, CHRU de Tours, Tours, France
3 shared publications
Latest Publications
- 1 July 2014
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 41 (6) , 501-506
A radiometabolite study of the serotonin transporter PET radioligand [11C]MADAM
- 1 July 2014
- Published by Elsevier in Nuclear Medicine and Biology
- Vol. 41 (6) , 501-506
A radiometabolite study of the serotonin transporter PET radioligand [11C]MADAM
The dopamine D1receptor agonist (S)-[11C]N-methyl-NNC 01-0259 is not sensitive to changes in dopamine concentration-a positron emission tomography examination in the monkey brain
Dopamine D2 receptor positron emission tomography (PET) radioligands have proven useful for indirect assessment of the endogenous dopamine concentration in the living brain. On the contrary, dopamine D1 receptor antagonist radioligands have shown no sensitivity to changes in the dopamine concentration. A recent approach to enhance the sensitivity of radioligands to the dopamine concentration has been the development of dopamine D2 receptor agonist radioligands. The aim of this study was to evaluate the dopamine sensitivity of a dopamine D1 receptor agonist radioligand. For this purpose, we developed (S)‐[11C]N‐methyl‐NNC 01–0259 ((S)‐[11C]1) and characterized the receptor binding of (S)‐[11C]1 using in vitro receptor binding assays and in vivo PET measurements in monkeys. In vitro, both enantiomers of 1 were partial dopamine D1 receptor agonists, with (S)‐1 having a 10–50 times higher affinity than (R)‐1. PET studies in monkey confirmed the stereoselectivity of [11C]1 in vivo. In monkey, administration of the dopamine D1‐like receptor antagonist (R)‐(+)‐SCH 23390 decreased the striatal binding potential of (S)‐[11C]1 by 97%, but administration of the dopamine concentration enhancer d‐amphetamine did not affect (S)‐[11C]1 binding. We conclude that the agonist (S)‐[11C]1 provides specific binding to dopamine D1‐like receptors, possibly representing binding to the high‐affinity state of the receptors. The partial dopamine D1 receptor agonist radioligand has, however, no enhanced sensitivity to endogenous dopamine concentrations in comparison with antagonist radioligands. Synapse 67:586–595, 2013.
The dopamine D1receptor agonist (S)-[11C]N-methyl-NNC 01-0259 is not sensitive to changes in dopamine concentration-a positron emission tomography examination in the monkey brain
Dopamine D2 receptor positron emission tomography (PET) radioligands have proven useful for indirect assessment of the endogenous dopamine concentration in the living brain. On the contrary, dopamine D1 receptor antagonist radioligands have shown no sensitivity to changes in the dopamine concentration. A recent approach to enhance the sensitivity of radioligands to the dopamine concentration has been the development of dopamine D2 receptor agonist radioligands. The aim of this study was to evaluate the dopamine sensitivity of a dopamine D1 receptor agonist radioligand. For this purpose, we developed (S)‐[11C]N‐methyl‐NNC 01–0259 ((S)‐[11C]1) and characterized the receptor binding of (S)‐[11C]1 using in vitro receptor binding assays and in vivo PET measurements in monkeys. In vitro, both enantiomers of 1 were partial dopamine D1 receptor agonists, with (S)‐1 having a 10–50 times higher affinity than (R)‐1. PET studies in monkey confirmed the stereoselectivity of [11C]1 in vivo. In monkey, administration of the dopamine D1‐like receptor antagonist (R)‐(+)‐SCH 23390 decreased the striatal binding potential of (S)‐[11C]1 by 97%, but administration of the dopamine concentration enhancer d‐amphetamine did not affect (S)‐[11C]1 binding. We conclude that the agonist (S)‐[11C]1 provides specific binding to dopamine D1‐like receptors, possibly representing binding to the high‐affinity state of the receptors. The partial dopamine D1 receptor agonist radioligand has, however, no enhanced sensitivity to endogenous dopamine concentrations in comparison with antagonist radioligands. Synapse 67:586–595, 2013.
- 31 August 2010
- Published by Elsevier in NeuroImage
- Vol. 52, S61-S62
Amphetamine decreases binding of the novel alpha2C-adrenoreceptor radioligand [11C]ORM-13070 in monkey brain
- 31 August 2010
- Published by Elsevier in NeuroImage
- Vol. 52, S61-S62
Amphetamine decreases binding of the novel alpha2C-adrenoreceptor radioligand [11C]ORM-13070 in monkey brain
- 31 December 2008
- Published by Elsevier in NeuroImage
- Vol. 41, T38
Dopamine D2/3 receptor occupancy of apomorphine in the non-human primate brain does not support the existence of two affinity states in vivo
- 31 December 2008
- Published by Elsevier in NeuroImage
- Vol. 41, T38
Dopamine D2/3 receptor occupancy of apomorphine in the non-human primate brain does not support the existence of two affinity states in vivo
- 31 December 2008
- Published by Elsevier in NeuroImage
- Vol. 41, T91
COMT inhibition prevents the formation of lipophilic radiometabolites of catechols, — An example with (S)-[11C]N-methyl-NNC 01-0259
- 31 December 2008
- Published by Elsevier in NeuroImage
- Vol. 41, T91
COMT inhibition prevents the formation of lipophilic radiometabolites of catechols, — An example with (S)-[11C]N-methyl-NNC 01-0259
- 31 December 2008
- Published by Elsevier in NeuroImage
- Vol. 41, T90-90
Discovery and labeling of a homochiral high affinity 3,4-diarylpyrazoline as a candidate radioligand for in vivo imaging of cannabinoid type-1 receptors
- 31 December 2008
- Published by Elsevier in NeuroImage
- Vol. 41, T90-90
Discovery and labeling of a homochiral high affinity 3,4-diarylpyrazoline as a candidate radioligand for in vivo imaging of cannabinoid type-1 receptors
- 31 December 2008
- Published by Elsevier in NeuroImage
- Vol. 41, T85
Advancement in PET quantification using 3D-OP-OSEM PSF reconstruction with the HRRT
- 31 December 2008
- Published by Elsevier in NeuroImage
- Vol. 41, T85
Advancement in PET quantification using 3D-OP-OSEM PSF reconstruction with the HRRT
- 31 December 2008
- Published by Elsevier in NeuroImage
- Vol. 41, T103
Mapping of the norepinephrine transporter in man using PET with (S,S)-[18F]FMeNER-D2
- 31 December 2008
- Published by Elsevier in NeuroImage
- Vol. 41, T103
Mapping of the norepinephrine transporter in man using PET with (S,S)-[18F]FMeNER-D2
- 31 December 2008
- Published by Elsevier in NeuroImage
- Vol. 41, T102
Radiosynthesis of [11C]MNPA from the precursor (R)-(−)-2-hydroxy-10,11-acetonide-NPA and a preliminary test–retest PET analysis in monkey brain
- 31 December 2008
- Published by Elsevier in NeuroImage
- Vol. 41, T102
Radiosynthesis of [11C]MNPA from the precursor (R)-(−)-2-hydroxy-10,11-acetonide-NPA and a preliminary test–retest PET analysis in monkey brain